Tepotinib clinical trial data and future application trend analysis

Tepotinib (Tepotinib) is a highly selective METtyrosine kinase inhibitor, mainly used to treat patients with MET exon< /span>14Non-small cell lung cancer (NSCLC) patients with skip mutations (METex14). According to data from the global pivotal clinical trial VISION study, tepotinib has shown good efficacy in this type of patients. Studies have shown that its objective response rate (ORR) can reach more than 50%, and the median progression-free survival (PFS) is about 11.2 months, and the duration of response (DOR) of some patients taking first-line drugs even exceeded 30 months, showing the strong potential of tepotinib as a first-line treatment.

In terms of safety, Tepotinib was generally well tolerated. The most common adverse reactions were peripheral edema, nausea, diarrhea and fatigue, most of which were Grade 1-2. The incidence of serious adverse reactions is relatively low, and the discontinuation rate is also within acceptable limits. Most side effects can be effectively controlled with appropriate dose adjustment and supportive treatment. This good safety profile makes tepotinib also has high clinical application value in elderly patients.

Tepotinib has also shown positive efficacy in specific populations, including those who are older, have brain metastases, or have received multiple lines of therapy. Especially in Asian populations, research data shows that its ORR and survival data are superior. In addition, for patients with brain metastases, tepotinib also shows certain central nervous system activity, and some intracerebral lesions can be alleviated, suggesting that it still has high therapeutic potential in complex advanced diseases.

Looking forward, tepotinib is expected to further consolidate its positioning in first-line treatment and expand its indications to other MET abnormally driven solid tumors, such as gastric cancer and colorectal cancer. At the same time, research on drug resistance mechanisms and combination strategies with immunotherapy and other targeted drugs are also actively promoted. As more clinical data accumulates, tepotinib's role in the field of precision therapy will be further strengthened, providing more patients with personalized and effective treatment options.

Reference materials:https://www.drugs.com/